UAE Approves First Nasal Spray for Severe Allergic Reactions

Apr 29, 2026

64 min

Apr 29, 2026 15:30

UAE Drug Authority approves first nasal spray for severe allergic reactions

## UAE Leads Region with New Allergy Treatment

The Emirates Drug Establishment (EDE) has approved "EURneffy," the first adrenaline nasal spray for emergency treatment of severe allergic reactions, known as anaphylaxis. This makes the UAE the first in the region to authorize such a product.

## Innovative Alternative to Injections

Developed by ALK Abelló, EURneffy offers a non-injection alternative for administering epinephrine, crucial for managing acute allergic episodes. The nasal spray is available in 1 mg and 2 mg doses, with the appropriate dosage determined by the patient's weight.

## Enhancing Emergency Response

The nasal spray is designed for ease of use, allowing even untrained individuals to administer it quickly. This feature is vital as it reduces hesitation and accelerates response time, potentially saving lives during critical situations.

## Strategic Healthcare Advancement

Dr. Fatima Al Kaabi, Director General of EDE, highlighted the approval as part of the UAE's strategy to adopt innovative therapies that directly impact patient care. The move reflects the country's commitment to improving healthcare quality and preparedness for emergencies.

## Collaboration and Commitment

Ghassan Al Qatab, Regional General Manager at ALK Abelló, emphasized the importance of this development in providing effective and user-friendly treatment options. The partnership with EDE aims to advance pharmaceutical care in the UAE and the region.

Read the full story at the source

What you need to know to get Emirates ID?

Leave your details and get a guide as a gift to avoid mistakes

Article contents